Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759426 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436463 | 0.98 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436465 | 0.94 | MTNR1A (0.88) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436444 | 0.93 | MTNR1A (0.88) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436443 | 0.92 | MTNR1A (0.86) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436479 | 0.90 | MTNR1A (0.83) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13462138 | 0.90 | MTNR1A (0.82) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3589948 | 0.90 | MTNR1A (0.82) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436478 | 0.90 | MTNR1A (0.81) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13436473 | 0.89 | MTNR1A (0.81) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119633001-A | Application and method of gastrodin in preparation of MT1 agonist with selectivity | 昆明理工大学 | 2025-03-18 | — | — | CN | claimed |
| CN-108699056-A | Method for treating atopic dermatitis | 江伯伦 | 2018-10-23 | — | — | CN | claimed |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | CHIANG BOR LUEN (TW) | 2018-10-18 | — | — | US | claimed |
| WO-2017107567-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | CHIANG BOR-LUEN (CN) | 2017-06-29 | — | — | WO | claimed |
| US-20090306137-A1 | TREATMENT FOR DEPRESSIVE DISORDERS | VANDA PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | claimed |
| EP-2029136-A1 | TREATMENT FOR DEPRESSIVE DISORDERS | Vanda Pharmaceuticals Inc. (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007137227-A1 | TREATMENT FOR DEPRESSIVE DISORDERS | VANDA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007137224-A2 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1476152-A4 | USE OF MELATONIN ANALOGUES FOR INDUCTION OF GENERAL ANESTHESIA | UNIV IOWA RES FOUND (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1476152-A2 | USE OF MELATONIN ANALOGUES FOR INDUCTION OF GENERAL ANESTHESIA | University of Iowa Research Foundation (US) | 2004-11-17 | — | — | EP | claimed |
| US-6638966-B2 | 2-tri-halo-1-methyl-N-acetyl-5-methoxytryptamine and a carrier | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-10-28 | — | — | US | claimed |
| WO-2003070177-A2 | USE OF MELATONIN ANALOGUES FOR INDUCTION OF GENERAL ANESTHESIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-08-28 | — | — | WO | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-119633001-A | Application and method of gastrodin in preparation of MT1 agonist with selectivity | 昆明理工大学 | 2025-03-18 | — | — | CN | disclosed |
| EP-4502609-A2 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-0769024-A4 | HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF | GEN HOSPITAL CORP (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0769024-A1 | HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | disclosed |
| WO-1995035320-A1 | HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | MTNR1A, MTNR1B, TSLP | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.